the delayed phase. The aim of this study was to verify if A + D is superior to metoclopramide plus dexamethasone (M + D) in preventing delayed emesis in cancer patients receiving the same prophylaxis for acute emesis.
introduction
Cisplatin is considered one of the most emetogenic antineoplastic agents. Important progress has been achieved in the last 20 years in preventing nausea and vomiting induced by cisplatin-containing chemotherapy. For the prophylaxis of acute emesis (first 24 h after chemotherapy administration), current guidelines recommend a combination of aprepitant, a NK1 receptor antagonist (r.a.), plus a 5-HT3 r.a. and dexamethasone.
In 2006, when our study was planned, the Multinational Association for Supportive Care in Cancer (MASCC) antiemetic guidelines recommended the use of a combination of aprepitant plus dexamethasone (A + D) [1] for the prophylaxis of cisplatininduced delayed emesis (after 24 h from chemotherapy administration). This treatment was suggested on the basis of the results of the two studies in which A + D was found superior with respect to dexamethasone alone in days 2-5 (complete response 68% versus 47% and 75% versus 56%, respectively) [2, 3] . Unfortunately, dexamethasone alone cannot be considered the standard antiemetic therapy for preventing cisplatin-induced delayed emesis; in addition, these studies, as the others evaluating aprepitant for the prevention of anthracycline plus cyclophosphamide-induced emesis in breast cancer patients [4] , were not planned to evaluate the efficacy of aprepitant in preventing delayed emesis [5] . Due to the different antiemetic regimens used in the acute phase (and the different results achieved) the superiority of A + D with respect to dexamethasone alone could be due to a dependence effect on the results achieved on day 1.
Before the introduction of aprepitant in clinical practice, a combination of metoclopramide plus dexamethasone (M + D) or a 5-HT3 r.a. started 24 h after the chemotherapy administration and continued for at least 3 days was considered the best treatment to prevent cisplatin-induced delayed emesis [5] .
The aim of our study was to define the role of aprepitant in preventing cisplatin-induced delayed emesis by comparing the combination of A + D versus M + D in patients receiving the same combination of aprepitant, palonosetron, and dexamethasone for the prophylaxis of cisplatin-induced acute emesis.
methods patients
All consecutive adult chemotherapy-naïve cancer patients scheduled to receive cisplatin-containing chemotherapy at doses ≥50 mg/m 2 were asked to enter the study. Patients scheduled to receive cisplatin associated with docetaxel, paclitaxel and pemetrexed, requiring premedication with corticosteroids (i.e. dexamethasone 4 mg or 8 mg or prednisone 25 mg once or twice in the 24 h before chemotherapy) were also eligible. Exclusion criteria were: planned treatments on days 2-4 after chemotherapy with other agents except 5-fluorouracil, etoposide, teniposide, vincristine, vinblastine, vindesine, vinorelbine, and gemcitabine, presence of nausea and vomiting or use of antiemetic agents during the 24 h before the chemotherapy administration, a severe concurrent illness other than neoplasia, other causes of vomiting (e.g. gastrointestinal obstruction, central nervous system metastases, or hypercalcemia), contraindication to dexamethasone (e.g. active peptic ulceration or previous bleeding from peptic ulcer), concurrent treatment with glucocorticoids (unless administered at physiologic doses) or benzodiazepines (unless given at night for sedation) or radiotherapy, a white blood cell count of less than 3000/mm 3 or a platelet count of less than 70 000/mm 3 , pregnancy and breast-feeding.
study design and management
This was an independent multicenter, double-blind, parallel, and randomized 1 : 1 study aimed to evaluate the different efficacy of aprepitant versus metoclopramide, both combined with dexamethasone in the control of cisplatin-induced delayed emesis. All patients received the same prophylaxis for acute emesis and received the antiemetic combination for delayed emesis on days 2-4 after chemotherapy administration.
Randomization was done by our statistician using computer-generated random numbers. Double blinding was prepared by a specialized company. Each center received a block of 10 numbered, already randomized, blinded treatments to use in progressive order. The case record forms were reviewed and collected by an independent monitor paid with funds from the Italian Ministry of Health that vouched for the accuracy and completeness of the data. The data were recorded on a magnetic device, and only at the end of the data recording was the double-blind broken and the received treatment added to the patient's file.
Data analysis and interpretation of the results and the first draft of the manuscript have been approved by the principal investigators. All the investigators of the participating centers contributed to the final manuscript and agreed to submit it for publication. All researchers, including principal investigators have not received any payment. This study was approved by the ethics committee of each participating institution; all patients gave written informed consent.
antiemetic treatments
All patients received on day 1, a combination of 0.25 mg of palonosetron administered intravenously as a 30 s bolus, 30 min before the beginning of chemotherapy, followed by 12 mg of dexamethasone, diluted in 100 ml of saline and administered intravenously over a 15-min period. Aprepitant 125 mg was orally administered 1 h before chemotherapy.
Patients were randomly assigned to receive one of the following two oral antiemetic prophylaxes for delayed emesis: dexamethasone 8 mg once daily on days 2-4 plus aprepitant 80 mg daily on days 2 and 3 or dexamethasone 8 mg twice daily on days 2-4 plus metoclopramide 20 mg four times daily on days 2-4. The dose of dexamethasone used was half of that used in the arm with aprepitant because there is a pharmacokinetic interaction with aprepitant, which increases the plasmatic levels more than twice. As rescue medication, on day 1 to 5 after chemotherapy, prochlorperazine 10 mg suppositories or metoclopramide 10 mg intramuscularly were recommended.
clinical assessment
Patients filled out a diary card for days 1-6 in which they reported daily the presence, intensity, and duration of nausea and the number of vomiting episodes as well as any adverse events and any administered rescue treatment. Furthermore, patients filled out on day 1 (before chemotherapy) and on day 6 (referring to what happened on day 1-5 after chemotherapy) the Functional Living Index-Emesis (FLIE), the only specific questionnaire aimed at evaluating the impact of nausea and vomiting on the patient's quality of life [6] .
Intensity of nausea was evaluated daily using the visual analog scale (VAS), a 100 mm long horizontal bar containing no marking except for the anchor point at each end: 'no nausea' (left), 'worst nausea' (right). Duration of nausea was evaluated each day by summing all the periods in which the patient suffered from nausea.
The primary endpoint of this study was the rate of complete response (no vomiting and no rescue treatment) from day 2-5 after chemotherapy. The secondary endpoints on days 2-5 were rates of: complete protection [no vomiting, no rescue treatment, and no significant nausea (VAS < 25 mm)], total control [no vomiting, no rescue treatment, and no nausea (VAS < 5 mm)], no vomiting, no nausea (VAS < 5 mm), no significant nausea, mean number of emetic episodes in patients who vomited, mean maximum severity of nausea, and mean duration of nausea, both these latter in patients suffering from nausea.
Patients were evaluated according to the intention-to-treat principle.
statistical analysis
The sample size was calculated with the following assumptions. In cancer patients submitted to cisplatin-containing chemotherapy and receiving as antiemetic prophylaxis for acute emesis a 5-HT3 r.a. plus dexamethasone, complete response on day 1 (no vomiting and no antiemetic rescue treatment) is about 73%, while adding aprepitant is about 85%. On day 2-4 after cisplatin administration, the combination of M + D induced a complete response on 62% of the patients [7] . These patients received for the prophylaxis of acute emesis a 5-HT3 r.a. and dexamethasone alone; therefore, we estimated that the addition of aprepitant on day 1 should determine a complete response for delayed emesis in at least 65% of the patients in the control arm. Considering an increase of at least 12% of complete response from delayed emesis (from 65% to 77%) as clinically relevant and fixing a significance level of 5% for a two-sided test able to compare the rates of complete response between the two independent samples, 240 patients per arm were necessary to detect a significant difference with a probability of 80%.
Fisher's exact test was used to compare the two groups with respect to all endpoints expressed by a binary variable, as well as to evaluate the differential safety. The Mann-Whitney U test was used to compare two means. All tests were two-sided and a significance level of 0.05 was fixed.
results
Nineteen patients did not complete the diary card: seven patients in the A + D arm and 12 in the M + D arm. All these 19 patients were excluded from the analysis.
Therefore, 284 patients were fully evaluated, 137 in the M + D arm, and 147 in the A + D arm.
The study was closed before reaching the dimension fixed in the protocol for accrual difficulties in many centers. The reduction of sample size with respect to that fixed in the protocol (480 evaluable patients) led to a decrease of the power from 80% to 62%.
Patient characteristics (Table 1 ) and the results observed in the acute phase, when all patients received the same antiemetic prophylaxis (Table 2 ), were both not significantly different between the two arms.
delayed nausea and vomiting
During days 2-5 complete response was similar with both antiemetic prophylaxes (82.5% with M + D and 80.3% with A + D); therefore, aprepitant was not superior to metoclopramide when both were combined with dexamethasone. The results relating to all the secondary endpoints were again not significantly different between the two groups, even if the rate of no significant nausea was slightly superior in the metoclopramide than in the aprepitant arm (Table 3 ). The impact of nausea and vomiting on patient quality of life, assessed by the FLIE questionnaire, was again not significantly different between the two groups (data not reported).
adverse events
The adverse events reported on day 1, when patients received the same antiemetic prophylaxis, had a similar incidence in the two groups (data not shown). During the delayed phase, the incidence of adverse events was not significantly different between the two arms (Table 4) . prophylaxis in the first 24 h (aprepitant plus ondansetron plus dexamethasone versus ondansetron plus dexamethasone, respectively), and therefore, this recommendation is opinion-based.
The results of our study show that in untreated patients submitted to cisplatin-based chemotherapy and receiving the optimal prophylaxis for acute emesis, the combination of A + D is not superior to that of M + D, but has the same efficacy in the control of delayed emesis and a similar toxicity.
Despite the negative results of this study, there are two main reasons that make them important.
First, these results should change the recommendations regarding the prophylaxis of cisplatin-induced delayed emesis. A combination of either A + D or M + D can be recommended.
Generally, in daily clinical practice, the choice between two drugs should be made considering the different efficacy, safety profile, and costs. Concerning efficacy, both combinations achieved the same complete response for delayed emesis and the rates of no vomiting and no nausea were similar. Furthermore, the two combinations are both well tolerated. Finally, the costs are very different: in Italy, the cost of two tablets of aprepitant for the prevention of delayed emesis is about sevenfold superior to that of metoclopramide. On 26 July 2013 the European Medicines Agency (EMA) recommended changes to the use of metoclopramide to reduce the risk of neurological side-effects such a short-term extrapyramidal disorders and tardive dyskinesia. Metoclopramide should be prescribed for short-term use (up to 5 days) and at a maximum dose [10] . At present, this recommendation has not been done by FDA. No extrapyramidal reactions have been reported by our patients. Second, our results suggest that only an appropriate methodology allows us to identify the role of an antiemetic agent. The combination of A + D was considered the standard prophylaxis for cisplatin-induced delayed emesis only on the basis of the results of two studies that, having two different antiemetic treatments for the first 24 h, make it impossible to exclude a dependence effect (carry-over) on the results of acute emesis.
Due to difficulty in the accrual of patients, the study was ended before reaching the dimension fixed in the protocol; and therefore, the most important shortcoming of our study is its low power (62% instead of 80%). Therefore, a small difference between the two antiemetic treatments could have been missed. In spite of this, there are several reasons to consider sufficiently reliable the results obtained. First, for calculating the sample size in antiemetic studies of superiority, the difference between the two antiemetic regimens is generally fixed at 15%; instead, in our study, it was 12%. If we had adopted the standard (15%), with 137 + 147 enrolled patients, the power of our study would have been 76%, not very far from the conventional 80% generally required. Furthermore, the primary endpoints and, with one exception, all the secondary endpoints were better in the metoclopramide than in the aprepitant arm, although these differences were not significant. Finally, the results obtained are confirmed by those reported in our previous study [11] , of a not superior efficacy of aprepitant with respect to another regimen not containing aprepitant for preventing delayed emesis. In our opinion, this latter point is particularly relevant. In this regard, comparing the results of this study with those of our previous study [11] , it seems that the cisplatin-and anthracycline-treated patients are protected against delayed emesis in a similar way. This leads us to some considerations on the emetogenicity of the chemotherapies, which today for ethical reasons, can only be evaluated by considering their conditioning by the received antiemetic prophylaxis. From this perspective, cisplatin and anthracycline containing chemotherapies seem to have a similar emetogenic potential, given the prophylaxis for delayed emesis recommended by the current antiemetic guidelines.
The better results obtained in the delayed phase by our study with respect to the anthracycline study could be due to the use of two antiemetic drugs instead of one. If this hypothesis is true, in anthracycline-treated patients, the efficacy of the prophylaxis for delayed emesis recommended by the current antiemetic guidelines may be improved by adding metoclopramide. Obviously, this should be shown by a well-planned future study.
The results of this study have been achieved using in the first 24 h palonosetron, a long acting 5-HT3 antagonist recognized for some delayed emesis efficacy. Of course it is not possible to know if similar results would be obtained with another shortacting 5-HT3 antagonist as ondansetron or granisetron.
In conclusion, this is the first study comparing with an appropriate methodology the effectiveness of the combination of M + D with respect to that of A + D in preventing cisplatin-induced delayed emesis. The effectiveness and safety profile of the two combinations are similar, but their different costs should lead to choosing M + D for the prophylaxis of cisplatin-induced delayed emesis.
